We are searching data for your request:
Upon completion, a link will appear to access the found materials.
Scientific data is communicated in many ways. Successful scientific careers require both written and oral presentations, and scientific reputations are based on both. It is important to know that every presentation, no matter how informal, will build or hurt your reputation.
Seminars, group meetings, ten-minute talks, and journal clubs are all ways scientists share data orally. While the content, length and purpose of each talk varies, they share certain common elements, including organization, clarity, and proper attribution for the work.
The oral presentations you will give in this class will be ten-minute talks. Your talks will include an introduction to the topic, a presentation of data, a summary and a time to answer questions from your classmates. Realistically, only two or three ideas can be effectively conveyed in so short a time, and even that will require that you carefully plan what you will say and then practice saying it. You are expected to rehearse and ultimately deliver your talk with a timer running, and to adjust your presentation as needed to stay within the allotted time. Fairness to your classmates demands that you respect the ten-minute time limit.
In addition to the advice below, you should consult with our oral presentation instructor Atissa Banuazizi.
Things to Remember about Giving your Talk
- A 10' talk is not a 30' talk given very fast
- It will help if you memorize at least the first few sentences of your talk
- Think of ways to transition from one slide to the next ("In the next slide I'll show you some data that identifies the protein detected")
- Figure out how to work the lights, slide projector, curtains etc before you begin.
- Keep the lights as bright as possible. If you have to turn the lights off for some image to be properly seen, then remember to turn the lights back on. People can and do fall asleep during dark seminars
- Laser pointers or sticks should be used to direct attention to images on the screen. Be sure to always use a pointer with a specific purpose in mind, rather than constantly gesturing in the general vicinity of your slide; otherwise, the audience will not know what's important. Don’t aim your laser pointer at anyone since it can damage a person's eyes.
How to Deal with Nerves
- Consider it excitement and turn it into enthusiasm
- Remember that even the most experienced speakers get nervous right before a talk
- Speak in a louder voice
- Don't speak in a monotone
- Do practice your talk, which will help eliminate crutch words such as "so," "um," and "like"
|SECTION||MINUTES||NUMBER OF SLIDES||DO||DON'T|
- Set the scene for the data you will present - introduce key concepts that the audience will need to follow along
- At the beginning or end of the introduction, briefly state the overall scope and significance of the study - what is the central question and why is it interesting?
- Try to summarize background material with a model slide
- Assume you are addressing experts
- Give more information than is absolutely needed to understand the rest of your talk
- Put too much information on each slide. You can bring in a few details as you speak if you are using PowerPoint animation
- Present the data in a logical sequence, letting each slide build upon the last
- Include a title for each slide. The title should be the conclusion to be drawn
- Make every element of your slide visible to the entire room. This means 20 point font or greater
- Interpret each slide thoroughly and carefully
- Point out strengths and weaknesses of the data along the way
- Read your talk. Similarly, don’t read lists from slides
- Put too much information on each slide. Each slide should make only one point
- Ever say, "I know you can’t read this, but…" Everything on each slide should be legible.
- Be afraid to remind audience how the data fits into the overall question
- Review each of your main "messages"
- Say what the study contributed to the field
- Forget to acknowledge all contributors
|Question & Answer||?||0|
- Answer the question being asked. If you are unclear about the question, ask for clarification
- Respect every question and questioner
- Take too long with one question. If the topic is involved, suggest you meet after the talk to discuss it more
Rehearse Your Talk Several Times
Find video examples of talks at MIT Video.
Deadline to submit your abstract extended: 12 th April
Scientists from academia and industry are invited to submit abstracts describing original research in one of the conference scientific topics:
- Biobased polymers
- Biocatalysis and recombinant protein production
- Biofuels and bioenergy
- Biopolymers and plastics
- Environmental biotechnology
- Feeding the future
- General biotechnology
- Genomics and genome editing
- Industrial biotechnology biochemical engineering
- Marine biotechnology
- Mastering heterogeneity in microbial biotechnology
- Medical and pharmaceutical biotechnology
- Metabolic engineering
- Modelling and computational design
- Plant and agricultural biotechnology
- Synthetic biology
- Systems biology
- Vaccines, antibiotics and new antimicrobials
- Water treatment, biodegradation and recycling
The Scientific Committee will evaluate the abstracts and invite the authors to present:
- short oral presentation in the main programme, or
- flash poster presentation in the main programme (one-minute video presentation), or
- poster presentation in the virtual poster gallery.
Guidelines and instructions
- 1. Complete the registration form and pay the registration fees.
- Follow the link to the abstract submission form. by using the username and password employed at the registration form.
- Follow the instructions and submit your abstract.
The abstract title should be less than 160 characters and must not be written in capital letters. Non-standard abbreviations should be avoided in titles, but may be used in the text if they are defined at first usage. The abstract should include the name of the presenting author underlined and affiliations of all authors. The body of the abstract should not exceed 1600 characters including footnotes. Standard abbreviations and SI units must be used. Please ensure that your abstract does not include tables, charts, or figures.
The Scientific Committee will select the type of contribution (short oral presentation, flash poster presentation or virtual poster) based on the review of abstracts. Authors will receive abstract acceptance notifications with guidelines on how to upload oral, flash poster and poster presentations by 16 April. .
Important Submitting an abstract for presentation does not constitute registration for the conference. Abstract presenters must register to attend the conference by following the instructions for registration. The Scientific Committee will evaluate the abstract only if the registration fees have been paid by the author.
You can submit one abstract. If you need to edit the abstract you already submitted, modifications will not be accepted after the abstract submission deadline.
The corresponding author will receive an e-mail confirming the successful submission of the abstract. All abstracts will be evaluated by the Scientific Committee and you will be notified about acceptance of your abstract by email.
Abstracts should be checked for accuracy prior to submission. Once the abstract has been submitted, changes, corrections or rewording will be possible until the abstract deadline. After this date changes will not be possible. The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission. Abstract submission does not constitute registration for the conference. Abstract presenters must register to attend the conference by following the instructions for registration.
Note on terminology
Company refers to any medical commercial organization involved with research, such as pharmaceutical or biotechnology companies and medical device manufacturers.
Company-sponsored refers to all types of research (preclinical and clinical, pre- and post-marketing) that is directly sponsored and/or funded by a company. While this classification does not necessarily include research performed under other types of funding arrangement, such as investigator-sponsored or investigator-initiated trials or research (where companies are not involved with conference presentations or publications), those involved in submitting investigator-initiated study material to conferences are encouraged to consider following these recommendations.
Conference is used to refer to meetings, often organized by academic societies, that invite submissions (usually as abstracts) presenting research findings on an aspect of medicine or science. Such conferences have a scientific (or programme) committee that reviews and selects presentations to be given at the meeting from the submitted abstracts.
Abstract refers to those submitted for consideration to scientific and medical conferences (see above).
Presentation refers to posters or slides developed from abstracts accepted for presentation at such conferences.
Lead author refers to the person who normally presents study findings at a conference and is usually listed as the first author. This is often the Principal Investigator.
Society sponsor refers to a member of the society that is holding the conference, who acts as sponsor (or guarantor) of a submitted abstract.
Presenting author refers to the person on the author list who attends the conference and presents the poster or abstract.
Non-author presenter or local presenter refers to a person who presents on behalf of the author group, but who is not listed as an author.
Western Illinois University
These are the suggested guidelines for preparing your oral presentation, written by Dr. Shawn Meagher.
Guidelines for Oral Presentations
Talks will be allotted 15 minutes total. You should speak for approximately 12 minutes, and allow 3 minutes for questions. Prepare visual aids to accompany your talk. Use PowerPoint [CD-ROM, thumb drive, etc.].
Tips for Successful Oral Presentations
Use your talk to emphasize (repeatedly) 2 or 3 main points. Audience members will only be paying attention to you sporadically. Use the following tips to increase your chances of getting your message across.
Time distribution: Before your slides, begin with a brief Introduction (1-2 minutes), in which you describe the general research area and your results (1st time audience will hear them). With the slides, take 7-9 minutes to explain your Methods and Results (2nd time audience hears message). End the slides with a Summary or Conclusion that you want your audience to take home (3rd time).
Slides (number): Include only as many slides as you can discuss meaningfully in your allotted time. A common rule of thumb is no more than one slide for each minute you will be talking.
Slides (general): Limit each slide to a single idea. Make them as simple and large as possible so that they are readable from at least 50 ft. 18-24 pt font is a good size. If you can read your slides without a magnifier, you should be alright. Do not plan to back up through your slides in your presentation! If the same slide needs to be shown multiple times, make multiple copies.
Slides (data): Graphs are better than tables. If you must use tables, do NOT use ones directly from manuscripts or papers retype them, and include only critical information. Do not complicate unnecessarily. Put only 1 figure/graph per slide, and do not use 3-D unless the additional axis provides information.
Slides (text): Text slides can be used to describe the research goals and Methods (but figures are often better) and to emphasize your Conclusions.
- Telegraphic style is best
- Fewer than 42 characters per line
- Fewer than 14 lines per slide
Practice: You must practice (aloud) so that you stay within the time limit. Write your speech out (entirely) beforehand to make sure that you can make your points clearly and that you make smooth transitions.
Presentation: Speak slowly. Do not assume that audience members will figure anything out by themselves. For example, describe graph axes before you describe patterns in your data. Make eye contact with the audience and interact with your slides: point to parts you want the audience to consider (axes, trends, localities, structures, etc.) Deliver your talk with an outline based on your written text, so that you will not read (and bore the audience), but can find your place if you get lost. You may want to have your Introduction and Conclusion written in full so that you can get through it smoothly.
Slides (color): White text on blue background is easy on viewers' eyes. Black on white may be more legible, particularly if there is any room light. Be sure to use colors with high contrast, and remember that some audience members may be colorblind (careful of red and green, or blue and red).
PowerPoint: Avoid unnecessarily complex, distracting backgrounds. Do not use complicated transitions, animations or cute sounds. Keep the audience's attention on your content, not cute graphics.
Content of Author Guidelines: 1. General , 2. Ethical Guidelines , 3. Manuscript Submission Procedure , 4. Manuscript Types Accepted , 5. Manuscript Format and Structure , 6. After Acceptance .
The editors encourage submissions of original articles, review articles, reports of meetings, book reviews and correspondence in the form of letters to the editor. Oral Diseases does not accept case reports.
Please read the instructions below carefully for details on the submission of manuscripts, the journal's requirements and standards as well as information concerning the procedure after a manuscript has been accepted for publication in Oral Diseases. Authors are encouraged to visit Wiley Author Services for further information on the preparation and submission of articles and figures.
Please find the Wiley preprint policy here. Oral Diseases accepts articles previously published on preprint servers. Oral Diseases will consider for review articles previously available as preprints. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication.
Data Sharing and Data Accessibility
Oral Diseases expects data sharing. All accepted manuscripts will need to publish a data availability statement to confirm the presence or absence of shared data. The journal expects authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper. Review Wiley’s Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Sample statements are available here. If published, statements will be placed in the heading of your manuscript.
2. ETHICAL GUIDELINES
Oral Diseases adheres to the ethical guidelines given below for publication and research.
2.1. Authorship and Acknowledgements
Authorship: Oral Diseases adheres to the International Standards for Authors published by the Committee on Publication Ethics (COPE). All authors named on a paper should agree to be named on the paper, and all authors so named should agree to the submission of the paper to Oral Diseases and approve the submitted and accepted versions of the publication. Any change to the author list should be approved by all authors, including any author who has been removed from the list.
Oral Diseases also adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). According to the ICMJE authorship criteria should be based on 1) substantial contributions to conception and design of, or acquisition of data or analysis and interpretation of data, 2) drafting the article or revising it critically for important intellectual content and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3.
It is a requirement that the corresponding author submit a short description of each individual's contribution to the research and its publication. Upon submission of a manuscript all co-authors should also be registered with a correct e-mail addresses. If any of the e-mail addresses supplied are incorrect, the corresponding author will be contacted by the Journal Administrator.
For all articles, the journal mandates the CRediT (Contribution Roles Taxonomy), for more information please see Author Services.
Acknowledgements: Authors must acknowledge individuals who do not qualify as authors but who contributed to the research. Authors must acknowledge any assistance that they have received (e.g. provision of writing assistance, literature searching, data analysis, administrative support, supply of materials). If/how this assistance was funded should be described and included with other funding information. “Acknowledgements” should be brief and should not include thanks to anonymous referees and editors. Where people are acknowledged, a cover letter demonstrating their consent must be provided.
2.2. Ethical Approvals
Human Subjects: Experimentation involving human subjects will only be published if such research has been conducted in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki (version 2002) and the additional requirements, if any, of the country where the research has been carried out. Manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and written consent of each subject and according to the above mentioned principles. A statement regarding the fact that the study has been independently reviewed and approved by an ethical board should also be included.
Photographs of People: Oral Diseases follows current HIPAA guidelines for the protection of patient/subject privacy. If an individual pictured in a digital image or photograph can be identified, his or her permission is required to publish the image. The corresponding author must either submit a letter signed by the patient authorizing Oral Diseases to publish the image/photo, or complete the 'Standard Release Form for photographic consent' available at the top of this page or by clicking the “instructions and Forms” link on the ScholarOne Manuscripts submission site. The approval must be received by the Editorial Office prior to final acceptance of the manuscript for publication. Otherwise, the image/photo must be altered such that the individual cannot be identified (black bars over eyes, tattoos, scars, etc.). Oral Diseases will not publish patient photographs that will in any way allow the patient to be identified, unless the patient has given their express consent.
Editors reserve the right to reject papers if there are doubts as to whether appropriate procedures have been used.
Animal Study: When experimental animals are used the methods section must clearly indicate that adequate measures were taken to minimize pain or discomfort. Experiments should be carried out in accordance with the Guidelines laid down by the National Institute of Health (NIH) in the USA regarding the care and use of animals for experimental procedures or with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and in accordance with local laws and regulations.
2.3 Clinical Trials
Clinical Trials should be reported using the CONSORT guidelines available at www.consort-statement.org . A CONSORT checklist and flowchart should also be included in the submission material. Clinical trials can be registered in any free, public clinical trials registry such as http://www.clinicaltrials.gov or http://isrctn.org/ . A list of further registries is available at http://www.who.int/ictrp/network/primary/en/. As stated in an editorial published in Oral Diseases (12:217-218), 2006), all manuscripts reporting results from a clinical trial must indicate that the trial was fully registered at a readily accessible website. The clinical trial registration number and name of the trial register will be published with the paper.
2.4 DNA Sequences and Crystallographic Structure Determinations
Papers reporting protein or DNA sequences and crystallographic structure determinations will not be accepted without a Genbank or Brookhaven accession number, respectively. Other supporting data sets must be made available on the publication date from the authors directly.
2.5 Conflict of Interest and Source of Funding
All sources of institutional, private and corporate financial support for the work within the manuscript must be fully acknowledged, and any potential grant holders should be listed. Authors are also required to disclose any possible conflict of interest. These include financial (for example patent, ownership, stock ownership, consultancies, speaker’s fee). Information on sources of funding and any potential conflict of interest should be disclosed at submission under the heading “Acknowledgements”.
2.6 Appeal of Decision
The decision on a paper is final and cannot be appealed.
2.7 Avoiding allegations of plagiarism
The journal to which you are submitting your manuscript employs text matching software (iThenticate) to ensure against plagiarism. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published work. Authors should consider whether their manuscript may raise concerns via iThenticate, which will signal whether a paper is likely in any way to be plagiarized in a formal sense. iThenticate will also, however, signal whether a paper may be plagiarized by repeating work of the submitting authors and thus be regarded as duplicate or redundant publication. Experience shows that, on occasion, large sections of submitted manuscripts can be close to verbatim in word choice from that seen in other papers from the authors’ group. This has nothing to do with simple repetition of names/affiliations, but does involve common (not necessarily "standard") phrases that are more appropriately referenced instead of repeating. Alternatively, they can be rephrased differently. Previously published results, including numerical information and figures or images, should be labeled to make it clear where they were previously reported. Papers that present new analyses of results that have already been published (for example, subgroup analyses) should identify the primary data source, and include a full reference to the related primary publications. Oral Diseases will review and publish accepted mansucripts that report data included in conference proceedings in abstract form. In such cases, authors must be clear to readers that part of all of the manuscript's data have already been published in abstract form by so indicating using a footnote to the title that states the confrence proceedings in which the relevant abstract was published. For full guidance on text matching and plagiarism, please refer to Section 3 ('Research Integrity') of Wiley's Ethics Guidelines at https://authorservices.wiley.com/ethics-guidelines/index.html.
If all or parts of previously published illustrations are used, permission must be obtained from the copyright holder concerned. It is the author's responsibility to obtain these in writing and provide copies to the Publishers.
3. MANUSCRIPT SUBMISSION PROCEDURE
Oral Diseases only accepts online submission of manuscripts. Manuscripts should be submitted at the online submission site: http://mc.manuscriptcentral.com/odi . Complete instructions for submitting a manuscript are available at the site upon creating an account. Assistance for submitting papers can be sought with the editorial assistant at: [email protected]
Data protection: By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.
Article Preparation Support
Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence. Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.
3.1. Manuscript Files Accepted
Manuscripts should be uploaded as Word (.doc/.docx) or Rich Text Format (.rft) files (not write-protected) plus separate figure files. GIF, JPEG, PICT or Bitmap files are acceptable for submission, but only high-resolution TIF or EPS files are suitable for printing. The files will be automatically converted to HTML and PDF on upload and will be used for the review process. The text file must contain the entire manuscript including title page, abstract, text, references, acknowledgements, tables, and figure legends, but no embedded figures. In the text file, please reference figures as for instance 'Figure 1', 'Figure 2' etc to match the tag name you choose for individual figure files uploaded. Manuscripts should be formatted as described in the Author Guidelines below.
3.2. Transparent Peer Review
This journal is participating in a Peer Review Transparency initiative. By submitting to this journal, authors agree that the reviewer reports, their responses, and the editor’s decision letter will be linked from the published article to where they appear on Publons in the case that the article is accepted. Authors have the opportunity to opt out during submission, and reviewers may remain anonymous unless they would like to sign their report. Read more about this initiative here.
3.3. Suggest a Reviewer
Oral Diseases attempts to keep the review process as short as possible to enable rapid publication of new scientific data. In order to facilitate this process, you must suggest the names and current e-mail addresses of from 2-4 potential reviewers whom you consider capable of reviewing your manuscript in an unbiased way.
3.4. Suspension of Submission Mid-way in the Submission Process
You may suspend a submission at any phase before clicking the 'Submit' button and save it to submit later. The manuscript can then be located under 'Unsubmitted Manuscripts' and you can click on 'Continue Submission' to continue your submission when you choose to.
3.5. E-mail Confirmation of Submission
After submission you will receive an e-mail to confirm receipt of your manuscript. If you do not receive the confirmation e-mail after 24 hours, please check your e-mail address carefully in the system. If the e-mail address is correct please contact your IT department. The error may be caused by some sort of spam filtering on your e-mail server. Also, the e-mails should be received if the IT department adds our e-mail server (uranus.scholarone.com) to their whitelist.
3.6. Manuscript Status
The average time from submission to first decision for manuscripts submitted to Oral Diseases is 20 days. You can access ScholarOne Manuscripts (formerly known as Manuscript Central) any time to check your 'Author Centre' for the status of your manuscript. The Journal will inform you by e-mail once a decision has been made.
3.7. Submission of Revised Manuscripts
To upload a revised manuscript, locate your manuscript under 'Manuscripts with Decisions' and click on 'Submit a Revision'. Please remember to delete any old files uploaded when you upload your revised manuscript.
4. MANUSCRIPT TYPES ACCEPTED
Original Research Articles: Manuscripts reporting laboratory investigations, well-designed and controlled clinical research, and analytical epidemiology are invited. Studies related to aetiology, pathogenesis, diagnosis, prevention and treatment are all of interest, but all papers must be based on rigorous hypothesis-driven research. Areas of interest include diseases affecting any structures of the mouth cancer and pre-cancerous conditions saliva and salivary glands bone and hard tissues relationaship between oral, periodontal, and dental conditions and general health pain behavioral dentistry chemosensory, developmental, geriatric, and motor disorders.
Randomised trials must adhere to the CONSORT guidelines, and a CONSORT checklist and flowchart must be submitted with such papers. Please also refer to the notes under section 2.3 above.
Oral Diseases supports the ALLTRIALS initiative and encourages authors submitting manuscripts reporting a clinical trial to register the trials in any of the following free, public clinical trials registries: www.clinicaltrials.gov, http://clinicaltrials.ifpma.org/clinicaltrials/, http://isrctn.org/. The clinical trial registration number and name of the trial register will then be published with the paper.
Observational studies must adhere to the STROBE guidelines, and a STROBE checklist must be submitted with such papers. Diagnostic accuracy studies must adhere to the STARD guidelines, and a STARD checklist must be submitted with such papers.
Review Papers: Oral Diseases commissions review papers and also welcomes uninvited reviews. Systematic reviews with or without meta-analyses must adhere to the PRISMA guidelines, and a PRISMA checklist and flowchart must be submitted with such papers. The word limit for Review Papers is 4,000 words, with a maximum of two tables or images and 50 references.
Letters to the Editors: Letters, if of broad interest, are encouraged. They may deal with material in papers published in Oral Diseases or they may raise new issues, but should have important implications. Only one letter may be submitted by any single author or group of authors on any one published paper. Letters to the Editors should not include an abstract and are limited to 500 words, with a maximum of 1 figure and 10 references.
Case Reports: Oral Diseases does not accept case reports and instead recommends that authors submit to Clinical Case Reports an open access journal published by Wiley.
Meeting Reports: Will be considered by the editors for publication only if they are of wide and significant interest.
Short Communications: These are brief papers of any topic within the scope of Oral Diseasesabout significant and novel advances that are complete in research endeavor but not suitable for full publications. Short Communications should not include an abstract and are limited to 1000 words, with a maximum of 3 figures and 20 references. Short Communications should not be structured into sections.
Invited Reviews: These may be submitted by invitation of the Senior Editors only, and consist of around 2500-2750 words, with a maximum of one table or image and 25 references.
Commentaries: These may be submitted by invitation of the Senior Editors only.
Invited Editorials: These may be submitted by invitation of the Senior Editors only.
Invited Book Reviews: These may be submitted by invitation of the Senior Editors only.
5. MANUSCRIPT FORMAT AND STRUCTURE
Oral Diseases now offers Free Format submission for a simplified and streamlined submission process.
Before you submit, you will need:
- Your manuscript: this should be an editable file including text, figures, and tables, or separate files – whichever you prefer. All required sections should be contained in your manuscript, including abstract, introduction, methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in the highest resolution possible. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.
- An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)
- The title page of the manuscript, including:
- Your co-author details, including affiliation and email address. (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)
- Statements relating to our ethics and integrity policies, which may include any of the following (Why are these important? We need to uphold rigorous ethical standards for the research we consider for publication):
- data availability statement
- funding statement
- conflict of interest disclosure
- ethics approval statement
- patient consent statement
- permission to reproduce material from other sources
- clinical trial registration
If you are invited to revise your manuscript after peer review, the journal will also request the revised manuscript to be formatted according to journal requirements as described below.
5.1. Page Charge
Articles exceeding 6 published pages, including title page, abstract, references, table/figure legends and tables and figures, are subject to a charge of GBP70 per additional page. As a guide, one published page amounts approximately to 850 words, or two to four small tables/figures. Additional supplementary material (including text and figures), which does not fit within the page limits, can be published online only as supporting information.
Language: Authors should write their manuscripts in British English using an easily readable style. Authors whose native language is not English should have a native English speaker read and correct their manuscript. Spelling and phraseology should conform to standard British usage and should be consistent throughout the paper. A list of independent suppliers of editing services can be found at http://authorservices.wiley.com/bauthor/english_language.asp. All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication.
Presentation: Authors should pay special attention to the presentation of their findings so that they may be communicated clearly. The background and hypotheses underlying the study as well as its main conclusions should be clearly explained. Titles and abstracts especially should be written in language that will be readily intelligible to any scientist.
Technical jargon: should be avoided as much as possible and clearly explained where its use is unavoidable.
Abbreviations: Oral Diseases adheres to the conventions outlined in Units, Symbols and Abbreviations: A Guide for Medical and Scientific Editors and Authors. Non-standard abbreviations must be used three or more times and written out completely in the text when first used.
5.3. Structure: All papers submitted to Oral Diseases should include:
- Title Page
- Structured Abstract
- Main text
- (Figure Legends)
Title Page: should be part of the manuscript uploaded for review and include:
- A title of no more than 100 characters including spaces
- A running title of no more than 50 characters
- 3-6 keywords
- Complete names and institutions for each author
- Corresponding author's name, address, email address and fax number
- Date of submission (and revision/resubmission)
Abstract: is limited to 200 words in length and should contain no abbreviations. The abstract should be included in the manuscript document uploaded for review as well as separately where specified in the submission process. The abstract should convey the essential purpose and message of the paper in an abbreviated form set out under:
The Main Text of Original Research Articles should be organised as follows
Introduction: should be focused, outlining the historical or logical origins of the study and not summarize the results exhaustive literature reviews are inappropriate. It should close with the explicit statement of the specific aims of the investigation.
Materials and Methods must contain sufficient detail such that, in combination with the references cited, all clinical trials and experiments reported can be fully reproduced. As a condition of publication, authors are required to make materials and methods used freely available to academic researchers for their own use. This includes antibodies and the constructs used to make transgenic animals, although not the animals themselves. Other supporting data sets must be made available on the publication date from the authors directly.
(i) Clinical trials: As noted above, these should be reported using the CONSORT guidelines available at www.consort-statement.org . A CONSORT checklist should also be included in the submission material. Clinical trials can be registered in any of the following free, public clinical trials registries: www.clinicaltrials.gov, http://clinicaltrials.ifpma.org/clinicaltrials/, http://isrctn.org/ .As stated in an editorial published in Oral Diseases (12:217-218), 2006), all manuscripts reporting results from a clinical trial must indicate that the trial was fully registered at a readily accessible website. The clinical trial registration number and name of the trial register will be published with the paper.
(ii)Experimental subjects: As noted above, experimentation involving human subjects will only be published if such research has been conducted in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki (version 2002) and the additional requirements, if any, of the country where the research has been carried out. Manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and written consent of each subject and according to the above mentioned principles. A statement regarding the fact that the study has been independently reviewed and approved by an ethical board should also be included.Editors reserve the right to reject papers if there are doubts as to whether appropriate procedures have been used. When experimental animals are used the methods section must clearly indicate that adequate measures were taken to minimize pain or discomfort. Experiments should be carried out in accordance with the Guidelines laid down by the National Institute of Health (NIH) in the USA regarding the care and use of animals for experimental procedures or with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and in accordance with local laws and regulations.
(iii) Suppliers: Suppliers of materials should be named and their location (town, state/county, country) included.
Results: should present the observations with minimal reference to earlier literature or to possible interpretations.
Discussion: may usually start with a brief summary of the major findings, but repetition of parts of the abstract or of the results sections should be avoided. The section should end with a brief conclusion and a comment on the potential clinical relevance of the findings. Statements and interpretation of the data should be appropriately supported by original references.
Acknowledgements: Should be used to provide information on sources of funding for the research, any potential conflict of interest and to acknowledge contributors to the study that do not qualify as authors. All sources of institutional, private and corporate financial support for the work within the manuscript must be fully acknowledged, and any potential grant holders should be listed. Acknowledgements should be brief and should not include thanks to anonymous referees and editors. Where people are acknowledged, a cover letter demonstrating their consent must be provided.
References should be prepared according to the Publication Manual of the American Psychological Association (6th edition). This means in-text citations should follow the author-date method whereby the author's last name and the year of publication for the source should appear in the text, for example, (Jones, 1998). For references with three to five authors, all authors should be listed only on the first occurrence of the in-text citation, and in subsequent in-text occurrences only the first author should be listed followed by 'et al.'. The complete reference list should appear alphabetically by name at the end of the paper.
A sample of the most common entries in reference lists appears below. Please note that a DOI should be provided for all references where available. For more information about APA referencing style, please refer to the APA website. Please note that for journal articles, issue numbers are not included unless each issue in the volume begins with page one.
Example of reference with 2 to 7 authors
Beers, S. R., & De Bellis, M. D. (2002). Neuropsychological function in children with maltreatment-related posttraumatic stress disorder. The American Journal of Psychiatry, 159, 483–486. doi: 10.1176/appi.ajp.159.3.483
Ramus, F., Rosen, S., Dakin, S. C., Day, B. L., Castellote, J. M., White, S., & Frith, U. (2003). Theories of developmental dyslexia: Insights from a multiple case study of dyslexic adults. Brain, 126(4), 841–865. doi: 10.1093/brain/awg076
Example of reference with more than 7 authors
Rutter, M., Caspi, A., Fergusson, D., Horwood, L. J., Goodman, R., Maughan, B., … Carroll, J. (2004). Sex differences in developmental reading disability: New findings from 4 epidemiological studies. Journal of the American Medical Association, 291(16), 2007–2012. doi: 10.1001/jama.291.16.2007
Bradley-Johnson, S. (1994). Psychoeducational assessment of students who are visually impaired or blind: Infancy through high school (2nd ed.). Austin, TX: Pro-ed.
5.5. Tables, Figures and Figure Legends
Figures: All figures and artwork must be provided in electronic format. Please save vector graphics (e.g. line artwork) in Encapsulated Postscript Format (EPS) and bitmap files (e.g. half-tones) or clinical or in vitro pictures in Tagged Image Format (TIFF).
Detailed information on our digital illustration standards can be found at http://authorservices.wiley.com/bauthor/illustration.asp.
Unnecessary figures and parts (panels) of figures should be avoided: data presented in small tables or histograms, for instance, can generally be stated briefly in the text instead. Figures should not contain more than one panel unless the parts are logically connected.
Figures divided into parts should be labelled with a lower-case, boldface, roman letter, a, b, and so on, in the same type size as used elsewhere in the figure. Lettering in figures should be in lower-case type, with the first letter capitalized. Units should have a single space between the number and unit, and follow SI nomenclature common to a particular field. Unusual units and abbreviations should be spelled out in full or defined in the legend. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. In general visual cues (on the figures themselves) are preferred to verbal explanations in the legend (e.g. broken line, open red triangles etc).
Color figures may be published online free of charge however, the journal charges for publishing figures in colour in print. If the author supplies colour figures at Early View publication, they will be invited to complete a colour charge agreement in RightsLink for Author Services. The author will have the option of paying immediately with a credit or debit card, or they can request an invoice. If the author chooses not to purchase color printing, the figures will be converted to black and white for the print issue of the journal.
Guidelines for Cover Submissions
If you would like to send suggestions for artwork related to your manuscript to be considered to appear on the cover of the journal, please follow these general guidelines.
6. AFTER ACCEPTANCE
Wiley Author Services
When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. You will be asked to sign a publication license at this point as well as pay for any applicable APCs.
Copyright & Licensing
You may choose to publish under the terms of the journal’s standard copyright agreement, or Open Access under the terms of a Creative Commons License. Standard re-use and licensing rights vary by journal. Note that certain funders mandate a particular type of CC license be used. This journal uses the CC-BY/CC-BY-NC/CC-BY-NC-ND Creative Commons License.
Self-Archiving Definitions and Policies: Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions.
Proofs must be returned to the Production Editor within three days of receipt. As changes to proofs are costly, we ask that you only correct typesetting errors. Excessive changes made by the author in the proofs, excluding typesetting errors, will be charged separately. Other than in exceptional circumstances, all illustrations are retained by the publisher. Please note that the author is responsible for all statements made in their work, including changes made by the copy editor.
Oral Diseases is covered by Wiley-Blackwell's Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article.
Article Promotion Support
Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.
Wiley’s Author Name Change Policy
In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.
4. Dental implants and bisphosphonate therapy
Implant placement in patients on bisphosphonate therapy predisposes them to development of osteonecrosis of jaw. So prior to planning implants in such patients it is important to identify the type of bisphosphonate (oral or intravenous) they are taking. Various studies have been done to identify the incidence of osteonecrosis in patients on bisphosphonate therapy ( Tableਃ ):
Recent studies showed the incidence of osteonecrosis in patients on bisphosphonate therapy.
Author Year Sample No. Of implants Bisphosph--onate therapy duration Mode of administration Incidence of osteonecrosis Marx 11 2005 119 cases of osteonecrosis in patients treated with oral bisphosphonates – 3 Oral 4 cases of osteonecrosis deriving from implants Jeffcoat 36 2006 25 patients 102 25 (for 3 years on average) Oral No case of osteonecrosis Wang 37 2007 1 5 1 (for more than ten years) Oral 1 Marx 38 2007 30 cases of osteonecrosis in patients treated with oral bisphosponates – 30 Oral 2 deriving from implant placement Fugazzotto 39 2007 61 169 61 (3 year average) Oral Torus exposure around on post extraction implant which closed spontaneously after four weeks Grant 40 2008 115 468 89 (33 for more than 3 years) Oral None
From the various studies it has been seen that patients on oral bisphosphonate therapy do not always result in osteonecrosis of jaw but it also depends on the duration of the therapy. The American association of oral and maxillofacial surgeons do not contraindicate the dental implant placement in patients taking oral bisphosphonates for fewer than three years prior to surgery provide that they do not present with other risk factors such as medication with steroids or advance age. If the patient has been taking medicine for more than 3 years it has been recommended to stop the medicine for at least 3 months before carrying out any surgical procedure and once the healing is complete the drug can be taken.
23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy
ABOUT THE PROGRAM:
Speakers at this meeting will present the newest and often unpublished data relating to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.
The Program will include:
- John Goldman Prize
- Janet Rowley Prize
- iCMLf Prize
- Keynote lectures
- Special lectures
- Oral communications selected from submitted abstracts
- Brief oral communications selected from submitted abstracts
- Workshops for non-clinical scientists
- Meet-the-Expert Sessions
- Clinical and biology manned poster walks
- 2021 Saturday Clinical symposium
Upon completion of this CME activity, participants should be able to:
1. Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.
2. Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.
3. Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.
4. Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.
5. Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.
6. Assess the role of allogeneic stem cell transplantation in the management of CML.
7. Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.
8. Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.
9. Discuss patient reported outcomes and their role in the management of patients with CML.
Society for Conservation Biology
Presenters and organizers manage and submit proposals and abstracts via the ICCB Submission Site.
ICCB is not currently accepting abstracts for contributed presentations (oral and speed talks and poster presentations). The submission deadline was 14 May 2021.
Invited Talks in Accepted Symposia
ICCB is accepting abstracts for invited talks in accepted symposia until 15 August 2021.
Invited speakers submit abstracts to their respective symposia via the ICCB Submission System. Invited speakers ready to submit their abstracts should:
- Use your SCB credentials to log in to their ICCB Profile page (see link above - ICCB Submission System). Anyone who is new to SCB (i.e. is not already in the SCB database) should follow the steps to create a new account.
- From your ICCB profile page, follow the link to submit your invited talk. Read instructions carefully! It's important that you link your talk to your respective symposium.
Per ICCB's one-talk, one poster rule, individuals are limited to one talk or poster presentation total, including invited talks in accepted symposia.
Questions? Email [email protected]
ICCB 2021 Session Types
ICCB is no longer accepting proposals for symposia, roundtable discussions, training courses and workshops. The Congress is accepting abstracts for contributed presentations through 30 April 2021.
Learn about each of the five scientific / educational sessions at ICCB below and view what information is required for proposals for each session.
ICCB symposia feature multiple speakers who present their insights, perspectives and research on a focused conservation theme, topic, or issue through scientific talks and audience interaction.
Three types of symposia take place during that main scientific program:
- Regular Symposium (90-minutes): A maximum of five speakers (which may include the organizer) present 12-minute talks, each followed by a 3-minute Q&A with the audience. The final 15-minutes is dedicated to discussion, usually facilitated by the symposium organizer. If there are fewer than five speakers, talks or discussion can be extended beyond 15 mins but must be a multiple of 15 mins (e.g., 30 mins). The most common symposium type at ICCB is 90-minutes.
- Extended Symposium (180-minutes): A maximum of ten speakers (which may include the organizer) present 12-minute talks, each followed by a 3-minute Q&A with the audience. Two 15-minute intervals (separate or back-to-back) are dedicated to discussion. If there are fewer than ten speakers, talks or discussion can be extended beyond 15 mins but must be a multiple of 15 mins (e.g., 30 mins). Extended symposia require a special justification from the organizer.
- Symposium with Roundtable Discussion (180-minutes): A Symposium with Roundtable Discussion features two 90-minute sessions, scheduled back-to-back whenever possible. The first 90-minutes is a regular symposium (see above) and the second 90-minutes is a roundtable discussion to allow for a deep and broad discussion of the symposium topic to develop tangible and actionable outputs.
Along with symosia, contributed presentations (oral and speed talks and poster presentations) make up the bulk of the ICCB scientific program. Contributed sessions are group abstracts by topic. Sessions last 90-minutes.
ICCB will provide format specifications for oral and speed talks and poster presentations (i.e. poster board size, projector screen size and aspect ratios, optimal PPT formats, video formats, etc) after the early bird registration deadline (September 2021).
Oral presentations share your research with participants in your contributed session and include an opportunity to interact with the audience. Oral presentations demonstrate why your research is valid and matters for conservation and explain the outcomes or expected outcomes of your research.
Roundtable Discussions bring together people with diverse expertise to develop tangible and actionable outputs &mdash such as a list of recommendations, a publication, a policy briefing or a white paper &mdash on a specific conservation issue. Roundtable Discussions are meant for discussion, collaboration, brainstorming, etc. They are not meant to consist of a series of presentations.
Roundtable Discussions can be held for a maximum of two days, for a duration between 1.5 and 8 hours. Roundtable Discussions of greater than three hours will be scheduled before the main scientific program.Roundtable Discussions of 1.5 or 3 hours (double session) will be scheduled during the main scientific program in dedicated time periods that do not conflict with symposia or contributed paper sessions. Roundtable Discussions typically have a smaller number of participants (10-30 maximum) than training courses or workshops. Pre and post-congress Roundtable Discussions may require a separate fee for participants in addition to the congress registration fee to offset the additional costs of running the session.
Training Courses provide opportunities for registered delegates to receive expert-led education and training on topics relevant for biodiversity conservation, including strategy and project management. ICCB 2021 prioritizes training courses that advance capacity for conservation action in Africa, though topics may be broadly applicable for global conservation solution / capacity building.
Training Courses may last up to two full days (8 hours each day) and will take place before the Congress on 11-12 December or after ICCB on 17 December. ICCB 2021 will consider training courses that include a virtual component whereby delegates can receive instruction online prior to arriving in Kigali.
Training session attendees pay a fee in addition to the conference registration fee. The fee is determined according to the cost of renting the room and the equipment required.
Workshops, whether geared toward students or professionals, are more interactive than symposia and often have an educational / technical component. Workshops share an approach, scientific finding, or technology that provides practical solutions for conservation challenges.
Workshops scheduled before or after the main scientific program and can vary in length from 4-to-16 hours. Lunchtime workshops are scheduled (90-minutes) are scheduled during the main scientific meeting.
ICCB is a global forum for addressing conservation challenges and for presenting new research in conservation science and practice.
1,500 conservation professionals and students in attendance, ICCB is the major networking event for anyone interested in conservation.
Authors may select from three presentation formats when submitting an abstract for AAIC. These include:
AAIC Poster Presentation (individual)
- Grouped by topic.
- An author may present multiple posters as long as they are scheduled on different dates.
- Poster format details will be provided in the spring.
AAIC Oral Presentation (individual)
- 15 minutes per presentation.
- Oral sessions are comprised of six presentations per oral session and are grouped by the AAIC Scientific Program Committee.
- The total length of one oral session is 1.5 hours.
- A person may be the presenting author on one podium presentation, excluding a developing topic session. A person may not present within an oral session and a featured research session. Invited speakers are not eligible for oral presentations. (Plenary and Symposium)
- Submitted oral presentation abstracts that are not selected may be considered for a poster presentation.
AAIC Featured Research Session (FRS)
- Featured Research Sessions (FRS) allow researchers to submit an entire session organized around a topic.
- One organizer is responsible for initiating the submission of the proposal (and confirming completeness) and the session speakers will be able to enter their individual abstract details. All session details and abstracts must be submitted by the deadline.
- One FRS is comprised of four presentations per session includes a total of four speakers and one to two session chairs, 1.5 hours total 22 minutes per presentation.
- Non-accepted FRS abstracts that receive an appropriate average review score will automatically be considered for an optional poster presentation. Find more information on the FAQ page.
- FRS presenters may apply for an AAIC Travel Fellowship. Submit an application via the abstract submission process. .
Facilities & instruments
The Periodontology Graduate Program operates a modern, well-equipped clinic which is located in the University of Minnesota's Health Sciences Center. Complete facilities for surgical and non-surgical periodontal therapy are available.
Clinical, research and office space is assigned to each graduate student throughout the training program. Collaborative clinical and didactic experiences are available with graduate students from: endodontics, oral pathology, orthodontics, oral surgery, pediatric dentistry, prosthodontics and others. Students within the fields of general dentistry, dental hygiene and dental assisting are available to assist during various clinical procedures.
The student to faculty ratio is 6 to 1 during clinic. Four of seven full-time divisional faculty members are diplomates of the American Board of Periodontology.
The Division of Periodontology supplies all clinical instruments at a moderate rental fee. Each student is required to have a high-quality camera, which is suitable for intraoral photography.
The Clinical Dental Research Center at the University of Minnesota is one of two centers in the United States sponsored by the National Institutes of Health.
Watch the video: 10 Donts σε μια παρουσίαση εργασίας ή διπλωματικής εργασίας - Πένα Φοιτητικές Εργασίες, Μεταφράσεις (November 2022).